నైరూప్య

Drug-Coated Balloon-Based Treatment of Unprotected de Novo Left Main Coronary Artery Disease

Tae Hyun Kim1,, Eun Jung Jun2,3,, Jinho Lee4, Chang Bae Sohn1, Byung Joo Choi1, Eun-Seok Shin2*

Objective: The aim of this study was to evaluate the safety and efficacy of DCB-based treatment for unprotected Left Main (LM) coronary artery disease.

Method: This retrospective registry study comprised a total of 42 consecutive patients diagnosed with unprotected de novo LM disease and stable hemodynamic conditions. A successful pre-balloon angioplasty was defined as achieving visual residual stenosis ≤ 30% without flow-limiting dissection and was followed by DCB (Drug Coated Balloon) treatment. Patients who did not meet these criteria were treated with a Drug-Eluting Stent (DES).

Results: Among the cohort of 42 patients, 23 individuals received DCB-only treatment, while based on the results of pre-balloon angioplasty, 19 patients were treated DES. Notably, no instances of bailout stenting or emergency coronary bypass surgery were observed following DCB treatment. Additionally, there were no reported cases of mortality or myocardial infarction within the DCB-only group during both hospitalization and the one-year follow-up period. Two patients (8.7%) experienced target lesion revascularization, all of whom presented with stable angina. A luminal increase was observed in 46.7% of cases, and the mean late lumen loss in the DCB-only treatment group was measured as 0.07 ± 0.45 mm.

Conclusion: DCB-based treatment of unprotected LM disease may be a safe and effective alternative to DES in carefully selected patients who have achieved successful predilation results. (Impact of Drug-Coated Balloon Treatment in de Novo Coronary Lesion; NCT04619277).